CAHCardinal Health
Is the price fair?
Neither cheap nor expensive: nothing decisive, though modest expectations priced in.
Priced for a decline (~−4% a year). The price demands less than its three-year revenue growth of 8% a year, expectations look modest.
In its normal range: P/E 13.9 vs a 13.8 median over 14 quarters (+1% vs median).
Sector median 22.6× across 130 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.
Unless marked, from derived, as of Dec 31, 2025.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What CAH's price assumes
Today's price asks for −4.4% free cash flow growth a year; over the last three years Cardinal Health delivered 25%, less than the record.
Price / sales · no trailing P/E on file: measured against sales instead
- Free cash flow yield
- 11%
Free cash flow yield · Healthcare median 4.8%
- Growth the price implies
- −4.4%
Growth the price implies · The price pays for −4.4% free cash flow growth a year for a decade; the business has delivered +25% a year over the last three.
- EV / sales
- 0.24
EV / sales
Details›
- EV / EBIToperating margin 1.0%: the multiple describes the denominator
- not meaningful
- EV / salestoday's price, trailing year to Dec 31, 2025
- 0.24
- Free cash flow, trailing twelve months
- $5.50B
- Market capitalisation
- $51.9B
- 3-year revenue growth
- +8.2%
- 3-year free cash flow growth
- +25%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.